Use of a contraceptive suppository as chemoprophylaxis against sexually-transmitted diseases
Marion-Landais, G.
Salud Publica de Mexico 23(4): 345-352
1981
ISSN/ISBN: 0036-3634 PMID: 6277015 Document Number: 180227
The incidence of sexually transmitted diseases (STD), especially gonorrhea, has risen dramatically in the past 2 decades. The population at greatest risk is also at high risk for unwanted pregnancies. Since currently employed treatment methods are failing to curb the problem, a search was instituted for an available vaginal contraceptive that would have a prophylactic effect against these diseases. In vitro studies have indicated that a vaginal contraceptive made of phenylmercuric acetate is an effective chemoprophylactic against Neisseria gonorrheae, Treponema pallidum, Candida albicans, Trichomonas vaginalis, and herpes simplex virus type 2. 2 clinical trials have shown that phenylmercuric acetate offered significant protection against gonorrheal infection. Although further testing is needed, the investigators concluded that phenylmercuric acetate was effective in reducing the incidence of gonorrheal infection and that the use of this agent could thus be of great value in combating a major health problem. The alarming increase in the incidence of STD throughout the world has resulted in a serious problem. The greatest increase has been in gonorrhea, with its incidence grown by 200% since 1958. Infections attributed to the other bacteria have also increased, although to a lesser extent. It is obvious that current treatment practices are failing to control the venereal disease epidemic. Considerable morbidity remains and the cost of combating these infections is high. Women with untreated gonococcal infections are at risk of developing salpingitis, with the possible sequelae of infertility due to tubal occlusion. This inability to bear children could be especially tragic as many of those who are at greatest risk are in their teens and early 20s. An agent which would provide both protection against these STD and contraceptive efficacy would be of great value. Since many of those in the high risk group do not have access to medical care, a vaginal contraceptive widely available without prescription would be likely to be used. This agent, made with phenylmercuric acetate is highly effective against these bacteria and trials have shown it to be good at reducing the incidence of gonorrheal infections in women. (author's)